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IMPORTANCE Rare variants in the complement genes CFH, CFI, C9, and C3 have been found to
be highly associated with age-relatedmacular degeneration (AMD); however, the effect on
clinical characteristics and familial segregation by these variants is lacking.
OBJECTIVES To determine the contribution of rare CFH Arg1210Cys, CFI Gly119Arg,
C9 Pro167Ser, and C3 Lys155Gln variants in the development of AMD in 22multiplex families
and to describe clinical differences in carriers vs noncarriers in these families and a large
case-control cohort.
DESIGN, SETTING, AND PARTICIPANTS This retrospective case-control study included 114
affected and 60 unaffectedmembers of 22multiplex families with AMD as well as 1589
unrelated patients with AMD and 1386 unrelated control individuals enrolled in the European
Genetic Database (EUGENDA). Patients were recruited fromMarch 29, 2006, to April 26,
2013, and data were collected from April 20, 2012, to May 7, 2014. All participants underwent
an extensive ophthalmic examination and completed a questionnaire. Venous blood samples
were obtained from all participants for genetic analysis, including whole-exome sequencing
andmeasurements of complement activation. Data were analyzed from September 23, 2014,
to November 4, 2015.
MAIN OUTCOMES ANDMEASURES Differences between carriers and noncarriers of rare
variants in age at onset of symptoms, the family history of AMD, complement activation
levels (C3d:C3 ratio), the presence of reticular pseudodrusen, and AMD phenotype.
RESULTS Among the 114 affected and 60 unaffectedmembers of 22multiplex families with
AMD and the 1598 unrelated patients with AMD and 1386 controls in the EUGENDA cohort
who underwent analysis, the presence of the CFI Gly119Arg, C9 Pro167Ser, or C3 Lys155Gln
variant was confirmed in 18 individuals in 5 families but did not completely segregate with the
disease. In the case-control cohort, the 91 affected carriers of these variants were younger at
symptom onset (mean [SD] age, 67.4 [8.5] vs 71.3 [8.9] years; P = .01) andmore often
reported a positive family history (35 of 79 [44.3%] vs 367 of 1201 [30.6%]; P = .008)
compared with the 1498 noncarriers. Patients with advanced atrophic AMD carried these rare
variants more frequently than patients with neovascular AMD (11 of 93 [11.8%] vs 40 of 835
[4.8%]; P = .04).
CONCLUSIONS AND RELEVANCE Previously reported rare variants do not completely
segregate within families with AMD. However, patients carrying these rare variants differ
clinically from noncarriers by an earlier age at symptom onset, higher prevalence of a positive
family history, and AMD phenotype. These results suggest that genetic tests for AMDmight
be designed to detect common and rare genetic variants, especially in families, because rare
variants contribute to the age at onset and progression of the disease.
JAMA Ophthalmol. 2016;134(3):287-293. doi:10.1001/jamaophthalmol.2015.5592
Published online January 14, 2016.
Supplemental content at
jamaophthalmology.com
Author Affiliations:Department of
Ophthalmology, Radboud University
Medical Center, Nijmegen, the
Netherlands (Saksens, Geerlings,
Bakker, Boon, de Jong, Hoyng,
den Hollander); Department of
Ophthalmology, University Hospital
of Cologne, Cologne, Germany
(Schick, Fauser); Department of
Nephrology, Leiden University
Medical Center, Leiden, the
Netherlands (Daha); Department of
Ophthalmology, Leiden University
Medical Center, Leiden, the
Netherlands (Boon); Department of
Human Genetics, Radboud University
Medical Center, Nijmegen, the
Netherlands (den Hollander).
Corresponding Author: Anneke I.
den Hollander, PhD, Department of
Ophthalmology, Radboud University
Medical Center, PO Box 9101, 6500
HBNijmegen, the Netherlands
(anneke.denhollander@radboudumc.nl).
Research
Original Investigation
(Reprinted) 287
Downloaded From: http://jamanetwork.com/ by a Radboud University Nijmegen User  on 12/21/2016
Copyright 2016 American Medical Association. All rights reserved.
A ge-relatedmacular degeneration (AMD) is the leadingcause of irreversible, central visual loss in the elderlypopulation in developed countries.1 A combination of
genetic and nongenetic factors plays a role in the develop-
mentandprogressionof thismultifactorialdisease.2,3Genome-
wide association studies have identified commongenetic risk
variants that are strongly associated with AMD, such as the
Tyr402His (rs1061170) variant in the complement factor CFH
gene (HGNC 4483) and the Ala69Ser (rs10490924) variant in
the age-related maculopathy susceptibility 2 (ARMS2) gene
(HGNC 32685).2,4,5
Previous family and twin studies have demonstrated a
strong genetic component and aggregation of AMD within
families.6-9 Approximately 20% to 30%of the patients have a
positive family history for AMD,7,10-12 which has been re-
ported as a significant risk factor for AMD. A positive family
history also has been associated with an earlier age at onset
of disease.13-17 Clustering of known common genetic risk fac-
torsdoesnot fully explain thenumberof affected familymem-
bers in large, densely affected families.7 Several recent stud-
ies have identified rare genetic variants that strongly increase
the risk forAMD, includingCFHArg1210Cys,CFI (HGNC5394)
Gly119Arg, C9 (HGNC 1358) Pro167Ser, and C3 (HGNC 1318)
Lys155Gln.15,18-21 These rarevariants are located ingenesof the
complement system, which plays a major role in the patho-
genesisofAMD.2,22Owing to their strongeffect size, these rare,
highly penetrant genetic variants may account for clustering
ofAMDin familiesand lead tomoreseveredisease.Highlypen-
etrantvariantshavebeen identified in familieswithAMD, thus
confirming the hypothesis that rare variants cluster in
families.15-17Understandingthecontributionsof theserarevari-
ants to the clinical characteristics of AMD is important be-
cause carrying these variants may have diagnostic, predic-
tive, and therapeutic consequences for carriers.
The aim of the present study was to determine the con-
tribution of known rare genetic variants in the development
of AMD in largemultiplex families with AMD. In addition, we
aimed todescribedifferences in clinical characteristics in car-
riers compared with noncarriers of these rare genetic vari-
ants in families and a large case-control cohort.
Methods
Participants
In this retrospective study, we evaluated 114 affected and 60
unaffectedmembersof 22multiplex familieswithAMD. Inad-
dition,weanalyzedacase-control cohortof 1589unrelatedpa-
tients with AMD and 1386 unrelated control individuals from
the European Genetic Database (EUGENDA). This study was
approved by the ethics committees of Commissie Mensge-
bonden Onderzoek Regio Arnhem-Nijmegen and University
Hospital Cologne on research involving human subjects and
met the criteria of theDeclarationofHelsinki.23 Before enroll-
ment in EUGENDA, all participants provided written in-
formed consent and completed a detailed questionnaire on
their medical history, age at onset of first symptoms, family
history of AMD, and lifestyle factors. For the case-control co-
hort, a family history positive for AMDwas defined as at least
2 first-degree relatives (parents and/or siblings) with AMD or
possible AMD.
Patientswere recruited fromMarch 29, 2006, to April 26,
2013, and data were collected from April 20, 2012, to May 7,
2014. Each participant of the EUGENDA cohort and all mem-
bers of the 22 families underwent digital color fundus pho-
tography and spectral-domain optical coherence tomogra-
phy (OCT) (Spectralis;HeidelbergEngineering) after pupillary
dilation. Digital, nonstereoscopic, 30° color fundus photog-
raphy centered on the fovea was performed (TRC 50IX cam-
era; TopconCorporation). Spectral-domainOCTvolumescans
consisted of 19 or 37 parallel OCT B-scans for analysis, which
covered amacular area of 6 × 4mm.For eachOCTB-scan, the
mean of 20 images was derived using the automated real-
time function.24 Color fundus photographs and OCT scans of
both eyes of all individualswere evaluated by 2 independent,
certified reading center graders, including one of us (T.S.), ac-
cording to the standard protocol of the Cologne Image Read-
ing Center and Laboratory.24 We classified AMD by the pres-
ence of pigmentary changes with at least 10 small drusen
(diameter, <63μm) or the presence of intermediate (diam-
eter,63-124μm)or large (diameter,≥125μm)drusen intheEarly
Treatment Diabetic Retinopathy Study grid. Advanced AMD
was defined as AMDwith subfoveal geographic atrophy (GA)
or choroidal neovascularization (CNV) in at least 1 eye. Age at
onset of AMDwas defined as the age at which the first visual
symptomsoccurred. Controlswere classified as havingno ab-
normalities or only small drusen or pigmentary abnormali-
ties and were 60 years or older. In addition, in 479 individu-
als, infrared images and spectral-domain OCT images were
evaluated for the presence of reticular pseudodrusen by one
of us (T.S.).
Genotyping
Whole-exome sequencing was used to genotype 85 affected
membersof22multiplex familieswithAMD.Thesampleswere
sequencedat theErasmusMedical CenterusingDNAobtained
fromvenousbloodafter extractionusing standardprocedures.
TheDNAwas fragmentedusingshearingultrasonic technology
accordingtothemanufacturer’s instructions (AdaptiveFocused
Acoustics;Covaris, Inc), andaDNAlibrarypreparationkit (Kapa
Biosystems,Inc)wasusedonasequencingworkstation(Sciclone
NGS;CaliperLifeSciences).Exomecapturewasachievedusing
Key Points
Question:What is the contribution of known rare genetic variants
in the development of age-relatedmacular degeneration (AMD) in
large families with AMD?
Findings: Rare CFI Gly119Arg, C9 Pro167Ser, and C3 Lys155Gln
variants were confirmed in 5 of 22 large families with AMD but did
not completely segregate with the disease.
Meaning: Genetic tests for AMDmight be designed to detect not
only common but also rare genetic variants because rare variants
appear to contribute to the age at onset and progression of the
disease.
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anexomesolutionkit (NimblegenSeqCapEZV2;RocheNimble-
gen, Inc)designedtocapturemorethan44Mbofexonicregions.
Paired-end 2 × 100 sequencing was performed on a device
(HiSeq2000; Illumina, Inc)usinga reagentkit (TruSeqV3; Illu-
mina, Inc). Downstream analyses included demultiplexing
(CASAVA software; Illumina, Inc) and alignment to the hg19
reference genome (Genome Reference Consortium Human
Reference25 [http://www.ncbi.nlm.nih.gov/assembly/GCF
_000001405.25/]) by the Burrows-Wheeler alignment tool.26
AlignmentsweresortedbyPicard(http://broadinstitute.github
.io/picard)andsubsequentlyprocessedusingtheGenomeAnaly-
sis Toolkit (GATK) (indel realignment and Base-Quality Score
Recalibration).27Finally, polymerase chain reactionduplicates
weremarkedbyPicard,meandepthofcoveragewasdetermined
using the GATK, and Freemix values were estimated through
verifyBamid.28 Samples that passed technical quality control
metricsweregenotypedto thegenomicvariantcall format level
through theGATKhaplotype caller. Insertions, deletions, and
single-nucleotide variants were filtered separately using the
GATKVariant-QualityScoreRecalibrationandannotatedusing
the ANNOVAR tool.29
We used filtering steps to select the previously associ-
ated variants in the CFH (Arg1210Cys; rs121913059), CFI
(Gly119Arg; rs141853578),C9 (Pro167Ser; rs34882957), andC3
(Lys155Gln; rs147859257) genes fromtheexome files of the85
affected familymembers.Theannotationof the identifiedvari-
ants was confirmed by Sanger sequencing using primers de-
signedwith Primer3 software (http://primer3.ut.ee) (eTable 1
in theSupplement). Thevariantswere also analyzed in thepa-
tientsof the index familieswhodidnotcarry theexome(n = 15)
using Sanger sequencing.
Genotyping of the rare CFH Arg1210Cys, CFI Gly119Arg,
C9 Pro167Ser, and C3 Lys155Gln genetic variants was per-
formed inall 2975 includedparticipantsof theEUGENDAcase-
controlcohort.Genotypingof theCFIGly119Argvariantwasper-
formedusingacustom-madeassay(TaqMan;LifeTechnologies)
as described previously.18 Genotyping of theCFHArg1210Cys,
C9Pro167Ser,andC3Lys155Glnvariantswasperformedbycom-
petitive,allele-specific,polymerasechainreactionassays (KASP
SNP Genotyping System; LGC Group) for CFH as previously
described30 and C9 and C3 according to the manufacturers’
recommendations (eTable 2 in the Supplement).
ComplementMeasurements
Levels of complement component C3 and the activation frag-
ment C3d were measured in serum samples as described
previously.31 The C3d:C3 ratio was calculated as ameasure of
complement activation32 and is a strongmarker forAMD.31 For
thestatisticalanalysis, theC3d:C3ratiounderwentnatural loga-
rithm transformation.
Statistical Analysis
Data were analyzed from September 23, 2014, to November
4, 2015. The odds ratio (OR) of the presence of a rare variant
for AMDwas calculated by binary logistic regression analysis.
Statistical analyses were performed to study differences in
age at symptom onset, complement activation levels, family
history of AMD, and AMD subtype between patient carriers
and noncarriers of the rare CFI Gly119Arg, C9 Pro167Ser, or C3
Lys155Gln variant. We analyzed the mean values of the con-
tinuous traits, complement activation levels, and age at first
symptoms using independent-sample t tests and compared
the mean value using the Pearson χ2 test for the other vari-
ables. Data were analyzed using SPSS software (version 20.0;
SPSS, Inc).
Results
The rare CFIGly119Arg, C9 Pro167Ser, and C3 Lys155Gln vari-
ants were observed in 18 individuals in 5 of the 22 multiplex
familieswithAMD.Although thesevariants aggregatedwithin
these families, theydidnot segregate completelywith thedis-
ease (Figure 1). The CFH Arg1210Cys variant was not ob-
served in any of the 22 families.
Figure 1. Pedigrees of 5 FamiliesWith Age-RelatedMacular Degeneration
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Pedigrees depict results of segregation analysis of rare and common CFH
Tyr402His and ARMS2 Ala69Ser variants in patients with the rare CFI Gly119Arg,
C9 Pro167Ser, or C3 Lys155Gln variants of complement factor genes. Risk alleles
are indicated in red. Affected individuals are assigned grades representing AMD
stage (1 indicates early; 2, intermediate; 3, advanced with subfoveal geographic
atrophy; and 4, advanced with choroidal neovascularization). Outer circles mark
the individuals who underwent whole-exome sequencing.
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The CFI Gly119Arg variant was detected in family 1
(Figure 1A).Of the4affected individuals, 3were carriers of the
CFIGly119Arg variant. Affected individual II:4 lacked the CFI
Gly119Arg and carried theCFHTyr402His risk allele homozy-
gously. The youngest unaffected individual (64 years) car-
ried the risk-conferring CFI variant. In family 2 (Figure 1B), 2
rare variants,C9 Pro167Ser andC3 Lys155Gln,were identified
heterozygously.Althoughbothvariantswere foundonly in af-
fected individuals,neithervariantsegregatedfullywith thedis-
ease phenotype. The C3 Lys155Gln variant was found to clus-
ter in 2 additional families (Figure 1C and D). In family 3, the
C3Lys155Glnvariantwasdetected in2affected individuals (II:2
and II:4), who also carried the ARMS2 Ala69Ser and CFH
Tyr402His risk alleles homozygously. Individuals II:1 and II:3
had intermediateAMDwithout carrying the rare variant inC3
andwereheterozygous for the commonARMS2Ala69Ser and
CFH Tyr402His risk alleles. In family 4, 5 individuals carried
the C3 Lys155Gln variant, of whom 4 had AMD and 1 did not
(II:8). Individuals II:6 and II:7 carried theC3 variant andwere
diagnosed as having intermediate AMD. Their older siblings
II:4 and II:5, who did not carry the rare variant, did not de-
velop AMD, although they had a higher genotypic load of the
2 common variants. In addition to family 2, the C9 Pro167Ser
variant was also identified in family 5 (Figure 1E). Two af-
fected individuals carrying the variant had a more advanced
AMD stage than the affected noncarrier family members.
Within the 5 families, rare variantswere detected in 16 af-
fected individuals and 2 unaffected carriers (Table 1). Carry-
ing 1 of the variants in CFI, C9, or C3 resulted in an OR of 7.11
for AMD (95% CI, 1.23-40.98; P = .03).
The age at symptom onset was earlier in affected family
memberswhocarried the rareCFIGly119Arg,C9Pro167Ser, or
C3 Lys155Gln variant comparedwith affected noncarriers (64
vs69years;P = .25) (Figure2).Thecomplementactivation level
(C3d:C3 ratio)washigher in affected familymemberswhocar-
ried a rare variant in a complement gene comparedwith non-
carriers (1.43 and 1.18, respectively; P = .053) (Figure 2). Most
patientswith advancedAMD carried a rare variant. This find-
ing holds true for the single patient with GA and 5 of the pa-
tients with CNV (P = .17).
Five of 25 affected familymembers showed anAMDphe-
notype with reticular pseudodrusen, and all 5 patients car-
ried the rareCFIGly119Arg,C9Pro167Ser, orC3Lys155Glnvari-
ant.Carrying1of thesevariantswasassociatedwithdeveloping
reticular pseudodrusen (P = .02). ThePro167Ser variant in the
C9 gene appeared to segregate with the reticular pseudodru-
senphenotype in family5because individuals II:2andII:3,who
carried the rare variant, showed reticular pseudodrusen,
whereas individuals II:1 andII:4didnot.However, the rarevari-
ants in theCFI andC3 genes didnot segregatewith the reticu-
lar drusenphenotype. Individual II:1 of family 1 and individu-
als II:2 and II:6 of family4 showed the reticular pseudodrusen
phenotype, but this phenotypewas not observed in their sib-
lings who carried the same rare variant.
Next, the analyses were replicated in a large case-control
EUGENDA cohort, which was genotyped for the rare variants
CFHArg1210Cys,CFIGly119Arg,C9Pro167Ser,andC3Lys155Gln.
Of the 1589 patients and 1386 controls in the case-control co-
hort, we identified 91 carriers (5.7%) in theAMDcohort and 43
carriers (3.1%) in the control cohort (Table 1). The CFH
Arg1210Cysvariantwasnotpresent inour case-control cohort.
Thepresenceof a rare genetic variantwas associatedwith
AMDand conferred anORof 1.90 (95%CI, 1.31-2.75;P = .001).
This association was comparable with the OR for advanced
AMD (OR, 1.90; 95% CI, 1.27-2.85; P = .002). Separate analy-
ses for each rare variant showed large effect sizes for the CFI
Gly119Arg variant (OR, 11.38; 95% CI, 1.49-87.06; P = .003),
whereas the effect sizes for theC9Pro167Ser variant (OR, 1.54;
95%CI, 0.96-2.45; P = .07) and the C3 Lys155Gln variant (OR,
1.81; 95% CI, 0.96-3.44; P = .06) were smaller (Table 2). Pa-
tients with AMD who carried the rare CFI Gly119Arg, C9
Pro167Ser, or C3 Lys155Gln variant reported a positive family
history for AMDmore often than patients with AMDwho did
not carry these rare variants (35 of 79 [44.3%] vs 367 of 1201
[30.6%], respectively;P = .008).Thisdifference inpositive fam-
ilyhistorywas the largest for carriers of theCFIGly119Argvari-
ant (58.3% vs 30.6%; P = .04), followed by variant Pro167Ser
in C9 (44.7% vs 30.6%; P = .04) (eTable 3 in the Supplement).
Inaddition,anearlierageatsymptomonsetwasfoundinpa-
tientswithAMDwiththerareCFIGly119Arg,C9Pro167Ser,orC3
Table 1. Clinical Characteristics of Carriers and Noncarriers of the Rare Variants in the 5 FamiliesWith AMD and the EUGENDA Cohort
Carrier and Disease Status
Female Sex,
No. (%)
Mean (SD) Age, y
Complement
Activation,
Mean (SD) ln
C3d:C3 Ratio
No. of Patients
With GA/CNV
Individuals With
Reticular Drusen,
No. (%)
At Participation
in EUGENDA
At Symptom
Onset
Families
Affected carriers (n = 16) 14 (87.5) 74.9 (10.2) 63.9 1.55 (0.38) 1/5 5/16 (31.3)
Affected noncarriers (n = 9) 5 (55.6) 71.4 (8.6) 69.4 1.51 (0.40) 0/1 0
Unaffected carriers (n = 2) 2 (100) 66.0 (4.2) NA 1.26 (0.37) NA 0
Unaffected noncarriers (n = 8) 4 (50.0) 66.9 (5.1) NA 1.41 (0.41) NA 0
EUGENDA cohort
Affected carriers (n = 91) 51 (56.0) 73.7 (8.4) 67.4 1.51 (0.35) 11/40 3/15 (20.0)
Affected noncarriers (n = 1498) 839 (56.1) 75.5 (8.9) 71.3 1.46 (0.34) 82/795 56/246 (22.8)
Unaffected carriers (n = 43) 29 (67.4) 70.2 (6.3) NA 1.26 (0.37) NA 0
Unaffected noncarriers (n = 1343) 764 (56.9) 70.4 (6.8) NA 1.37 (0.36) NA 0
Abbreviations: AMD, age-relatedmacular degeneration; CNV, choroidal neovascularization; EUGENDA, European Genetic Database; GA, geographic atrophy;
NA, not applicable.
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Lys155Glnvariant than inpatientswhodidnot carry these rare
variants(mean[SD]age,67.4[8.5]vs71.3[8.9]years,respectively;
P = .01) (Table 1andFigure2). In individualscarryingararevari-
ant, themeancomplementactivation level (lnC3d:C3ratio)was
higher in cases comparedwith controls (P < .001). In contrast,
themean lnC3d:C3 ratio inpatientswithAMDwhocarriedone
of the rarevariantswasnotdifferent fromthatofnoncarriersof
thesevariants(P = .85)(Figure2).InpatientswithadvancedAMD,
the rareCFIGly119Arg,C9Pro167Ser, andC3Lys155Glnvariants
werepresentmoreofteninpatientswithGA(11of93[11.8%])than
inpatientswithCNV(40of835[4.8%];P = .04).Areticularpseu-
dodrusenphenotypewaspresent in56of246patientswithAMD
andnoneof the 183controls (Table 1).Noassociationwas found
between the presence of reticular pseudodrusen and the pres-
ence of one of these rare variants in the large AMD cohort
(P = .80).
Discussion
ThedevelopmentofAMDindenselyaffectedfamiliescanbe in-
fluencedby rare genetic variants, ofwhich4 (CFHArg1210Cys,
CFIGly119Arg,C9Pro167Ser,andC3Lys155Gln)werepreviously
associatedwithAMD.15,18-21 InourEUGENDAcase-controlcohort,
thepresenceofavariantresultedinanORof1.90forAMD,which
is comparable with previously reported effect sizes for the C9
Pro167SerandC3Lys155Glnvariants.15,18-21However, theeffect
sizeof theGly119Argvariant in theCFIgenewasmuchstronger,
withanORof11.38,whichis inlinewiththoseofpreviousreports
(ORs,8.5and22.2).18,33TheCFHArg1210Cysvariantwasprevi-
ously associatedwithAMD inNorthAmerican cohorts15,20 but
not inIcelandic19andHanChinesecohorts.34Theabsenceofthis
variant inourAMDcase-control cohortmayreflect thedifferent
distribution of low-frequency alleles among populations.30
Almost half of the patientswho carried one of the rareCFI
Gly119Arg,C9Pro167Ser,orC3Lys155Glnvariantsreportedafam-
ily historypositive forAMD,whichhas important implications
for counseling of these patients and their familymembers and
underlines the importanceof includingtheserarevariants inge-
netic tests for AMD.Despite their strong associationwithAMD
incase-controlcohorts,18-21 theCFIGly119Arg,C9Pro167Ser,and
C3Lys155Gln variants didnot segregatewith thedisease in the
5 families in this study.This findingcouldpoint to thecontribu-
tionofothergeneticriskallelesandenvironmentalfactorsinsuch
Figure 2. Age at Onset and Complement Activation in Carriers vs Noncarriers of Rare Genetic Variants
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Analysis was performed in themembers of 5 families with age-relatedmacular
degeneration (AMD) and in AMD cases and controls from the European Genetic
Database (EUGENDA) cohort. The difference in age at onset between carriers
and noncarriers was not significant in the families (mean [SD] age, 63.9 [10.3]
vs 69.4 [7.1] years) but was significant in the EUGENDA cohort (67.4 [8.5] vs 71.3
[8.9] years). The complement activation ratio between carriers and noncarriers
in the families (1.427 vs 1.180) and EUGENDA cohort (1.463 vs 1.455) was not
significant. Lines indicate mean values. Ln indicates natural logarithm.
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multiplex families. Further research iswarranted todetermine
whether additional rare variants aggregate in the remaining 17
familieswith AMD in this study.
Patientswhocarryaknownraregeneticvariantdiffer clini-
cally from patients who do not. We demonstrated that carri-
ers of the rare CFI Gly119Arg, C9 Pro167Ser, or C3 Lys155Gln
variants have an onset of symptoms 4 years earlier, of which
theCFIGly119Argvariant shows the strongest effect.This find-
ing is comparable to the earlier onset previously described in
patients carrying the rareArg1210Cysvariant in theCFHgene15
and is in line with the earlier age at symptom onset in pa-
tients with familial AMD.14
Manyof thecommongeneticvariantsassociatedwithAMD
reside in genes encoding components of the complement
cascade,2,4,35-37 some of which have been associated with in-
creasedsystemic levelsof complementactivationandcomple-
ment components.25,31,38Nearly all the recently identified rare
variantsare located incomplementgenes,15,17-21,39-41 emphasiz-
ing the important role of the complement system in thepatho-
physiology of AMD. Mean complement activation levels were
slightly higher in patients with AMDwho carried rare variants
in the CFI, C9, or C3 gene comparedwith noncarriers, but this
difference incomplementactivation levelscannotbeexplained
by thepresenceof the rarevariantsevaluated in this study.Pre-
ventiveandtherapeuticoptions inhibiting thecomplementcas-
cadehavebeensuggested tobeeffective in treatingAMD,42but
our current results donot support thehypothesis that patients
whocarrya rarevariant inacomplementgenewillbenefitmore
fromsuch treatments thannoncarriers.However, complement
inhibition is a promising target for treatment of GA in AMD,43
which ismore prevalent in affected carriers than noncarriers.
In this study, rarevariantsweremore frequently identified
inpatientswithadvancedAMDandGAthanadvancedAMDand
CNV. This finding is in linewith that of a recent study,44which
observedahigherprevalenceofGAamongpatientscarryingthe
CFHArg1210Cys variant. A previous investigation14 suggested
thatadditionalgeneticfactorsmaycontributetothedevelopment
ofGAin familialpatientsbecauseahigherprevalenceofGAwas
foundinfamilial thansporadicAMDcases,andsiblingsaremore
likely todevelop thesameadvancedAMDsubtypeas their fam-
ilyproband.32The findingsof thecurrent studyare thusconsis-
tentwithoursuggestionthatadditionalgeneticfactorsplayarole
in GAdevelopment.14
From these findings, we recommend that patients of Eu-
ropean descent in densely affected families with AMD un-
dergo screening for rare CFI Gly119Arg, C9 Pro167Ser, and C3
Lys155Gln variants because these rare variants played a role
inmore than20%ofour screened families.However, these as-
sociations may not hold true within populations of other an-
tecedents because different rare variants in these popula-
tions may play a more important role, such as, for example,
CFH Arg1210Cys in the North American population.19
Conclusions
We observed a higher familial occurrence and an earlier age
at onset in the carriers of the rare genetic variants CFI
Gly119Arg,C9Pro167Ser, andC3Lys155Gln.These findingsem-
phasize the importance of counseling of patients and family
members to increase awareness and enable early detection of
the disease. Genetic tests for AMD should therefore be de-
signed to detect, in addition to the common variants, the de-
scribed rare genetic variants, especially in families, because
these rare variants contribute to the age at onset and progres-
sion of the disease.
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Table 2. Frequencies and Effect Sizes of the Rare Variants in the EUGENDA Cohort
Rare Variant of
Complement Factor Gene
No. (%) of Participants
OR
(95% CI) P Value
Patient Carriers
(n = 1589)
Control Carriers
(n = 1386)
CFI Gly119Arg 13 (0.8) 1 (0.1) 11.38 (1.49-87.06) .003
C9 Pro167Ser 49 (3.1) 28 (2.0) 1.54 (0.96-2.45) .07
C3 Lys155Gln 29 (1.8) 14 (1.0) 1.81 (0.96-3.44) .06
CFH Arg1210Cys 0 0 Abbreviations: EUGENDA, European
Genetic Database; OR, odds ratio.
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